Emergent BioSolutions - EBS Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares.
View EBS analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 12 month target prices for Emergent BioSolutions' stock. Their EBS share price forecasts range from $9.00 to $55.00. On average, they anticipate the company's stock price to reach $31.20 in the next twelve months. This suggests a possible upside of 300.5% from the stock's current price.
View analysts price targets for EBS or view top-rated stocks among Wall Street analysts.

Emergent BioSolutions' stock was trading at $11.81 on January 1st, 2023. Since then, EBS stock has decreased by 34.0% and is now trading at $7.79.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our EBS earnings forecast.

Emergent BioSolutions Inc. (NYSE:EBS) released its quarterly earnings results on Monday, February, 27th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of $0.31 by $0.62. The biopharmaceutical company had revenue of $330.70 million for the quarter, compared to analysts' expectations of $298.23 million. Emergent BioSolutions had a negative net margin of 19.97% and a negative trailing twelve-month return on equity of 7.57%. The firm's quarterly revenue was down 54.3% on a year-over-year basis. During the same period in the previous year, the company earned $4.50 earnings per share.

ETFs with the largest weight of Emergent BioSolutions (NYSE:EBS) stock in their portfolio include First Trust Nasdaq Pharmaceuticals ETF (FTXH), Invesco S&P SmallCap 600 Pure Value ETF (RZV), Cultivar ETF (CVAR), SPDR S&P Biotech ETF (XBI), ETFMG Treatments Testing and Advancements ETF (GERM), First Trust Small Cap Value AlphaDEX Fund (FYT), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Invesco S&P SmallCap Health Care ETF (PSCH).

Emergent BioSolutions updated its FY 2023 earnings guidance on Monday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.10 billion-$1.20 billion, compared to the consensus revenue estimate of $1.18 billion.

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Emergent BioSolutions' stock is owned by a number of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (3.69%), Man Group plc (1.76%), Geode Capital Management LLC (1.72%), Charles Schwab Investment Management Inc. (1.39%), Morgan Stanley (1.31%) and AQR Capital Management LLC (1.10%). Insiders that own company stock include Adam Havey, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Richard S Lindahl, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
View institutional ownership trends.

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EBS stock can currently be purchased for approximately $7.79.

Emergent BioSolutions (NYSE:EBS) has a market capitalization of $390.59 million and generates $1.12 billion in revenue each year. The biopharmaceutical company earns $-223,800,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis.

The company employs 2,500 workers across the globe.

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The official website for the company is www.emergentbiosolutions.com. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at burrowsr@ebsi.com, or via fax at 301-795-1899.